Altered expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cells

Cancer Biology and Therapy

Volumn 5, Issue 12, 2006, Pages 1632-1636

  Zhang, Jun ^a   Wang, Xianshu ^a   Lin, Chia Ju ^a   Couch, Fergus J ^a   Fei, Peiwen ^a  

^a Mayo Clinic   (United States)

Author keywords

A splicing variant of FANCL; Chemotherapy; Cisplatin resistance; Cisplatin sensitivity; FA BRCA pathway; FANCD2 monoubiquitination; FANCL; Fanconi anemia; Mitomycin C

Indexed keywords

FANCONI ANEMIA GROUP L PROTEIN; FANCONI ANEMIA PROTEIN; MITOMYCIN C; PROTEIN; PROTEIN BRCA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER PATIENT; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LUNG CANCER; PROTEIN EXPRESSION;

EID: 33846978430     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.12.3351     Document Type: Article

References (19)

1. Bagby GC. Genetic basis of Fanconi anemia. Curr Opin Hematol 2003; 10:68-76.
2. Fei P, Yin J, Wang W. New advances in the DNA damage response network of Fanconi anemia and BRCA proteins. FAAP95 replaces BRCA2 as the true FANCB protein. Cell Cycle 2005; 4:80-6.
3. Taniguchi T, D'Andrea AD. The molecular pathogenesis of fanconi anemia: Recent progress. Blood 2006; In press.
4. Andreassen PR, Ho G, D'Andrea AD. DNA damage responses and their many interactions with the replication fork. Carcinogenesis 2006; In press.
5. Alter BP. Cancer in Fanconi Anemia, 1927-2001. Cancer 2003; 97:425-40.
6. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, D'Andrea AD. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002; 297:606-9.
7. Levitus M, Waisfisz Q, Godthelp BC, de Vries Y, Hussain S, Wiegant WW, Elghalbzouri-Maghrani E, Steltenpool J, Rooimans MA, Pals G, Arwert F, Mathew CG, Zdzienicka MZ, Hiom K, De Winter JP, Joenje H. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 2005; 37:934-5.
8. Litman R, Peng M, Jin Z, Zhang F, Zhang J, Powell S, Andreassen PR, Cantor SB. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 2005; 8:255-65.
9. Meetei AR, de Winter JP, Medhurst AL, Wallisch M, Waisfisz Q, van de Vrugt HJ, Oostra AB, Yan Z, Ling C, Bishop CE, Hoatlin ME, Joenje H, Wang W. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet 2003. 35:165-70.
10. Fei P, El-Deiry WS. p53 and radiation responses. Oncogene 2003; 22:5774-83.
11. El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003; 22:7486-95.
12. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
13. Venkitaraman AR. Tracing the network connecting BRCA and Fanconi anaemia proteins. Nat Rev Cancer 2004; 4:266-76.
14. van der Heijden MS, Yeo CJ, Hruban RH, Kern SE. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003; 63:2585-8.
15. Couch FJ, Johnson MR, Rabe K, Boardman L, McWilliams R, de Andrade M, Petersen G. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 2005; 65:383-6.
16. Seal S, Barfoot R, Jayatilake H, Smith P, Renwick A, Bascombe L, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N. Breast cancer susceptibility collaboration. Evaluation of Fanconi Anemia genes in familial breast cancer predisposition. Cancer Res 2003; 63:8596-9.
17. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC, D'Andrea AD. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003; 9:568-74.
18. Guminski AD, Harnett PR, deFazio A. Scientists and clinicians test their metal-back to the future with platinum compounds. Lancet Oncol 2002; 3:312-8.
19. Fei P, Wang W, Kim SH, Wang S, Burns TF, Sax JK, Buzzai M, Dicker DT, McKenna WG, Bernhard EJ, El-Deiry WS. Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell 2004; 6:597-609.